1. <progress id="voycx"></progress>
    1. A LONG-TERM FOCUS
      ON INNOVATION

      We welcome the opportunity to discuss:

      BUSINESS
      DEVELOPMENT
      COLLABORATIONS

      • In-licensing and / or R&D collaborations
        • Creative collaborations in emerging fields
        • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
      • Strategic late-stage development and commercial partnerships with other leading biopharma companies
      • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

      Introduce your assets or discuss
      late-stage partnership

      ACADEMIC &
      RESEARCH
      COLLABORATIONS

      • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

      Learn more

      • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

      Learn more

      OUR BUSINESS DEVELOPMENT STRATEGY

      Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

      We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

      • Novel platforms that enable next-generation therapeutics
      • Technologies for antibody discovery and development against new / challenging targets
      • New approaches that enhance activity of tumor-directed antibodies
      • Biomarker discovery and validation
      • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
      • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
      • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

      SOME OF OUR CURRENT COLLABORATORS INCLUDE:


      BAYER logo

      Global ophthalmology
      collaborations

      SANOFI logo

      Antibody and immunotherapy
      collaborations

      Icahn School of Medicine at Mount Sinai logo

      Antibody discovery
      agreement

      Columbia University logo

      Research collaboration on genetic
      basis of familial disease

      TEVA logo

      Global collaboration for
      investigational pain therapeutic

      Intellia Therapeutics logo

      Gene-editing technology
      collaboration

      Adicet Bio logo

      Engineered immune cell
      therapeutics collaboration

      Alnylam Pharmaceuticals logo

      RNA interference (RNAi)
      therapeutics collaboration

      樱桃福利入口